Clinical Trial Update: Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating LNP023 (iptacopan) for safety, efficacy, tolerability, pharmacokinetics, and pharmacodynamics in patients with paroxysmal nocturnal hem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• LNP023 (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis | Phase 2 | Status: COMPLETED | Results posted: 2024-01-03